Just as I thought, Optiscan needed the SPP to fund ongoing operations. But if they now have money to see them through to the end of 2010, I'd say the SPP was a success. Throw in some income from grants, Hoya, and FIVE1, and they're not too badly placed at all.
Both the second generation rigid endoscope and the Zeiss collaboration have huge potential. It really only requires one of these to succeed (in getting certification, gaining acceptance, and generating decent sales) to produce significant income. That's still two or three years away, though.
Ann: AGM Address 2009 - text and slides , page-2
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OIL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $162.8M | |||
| Open | High | Low | Value | Volume |
| 18.5¢ | 19.5¢ | 18.5¢ | $24.65K | 130.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 86717 | 18.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.5¢ | 28000 | 2 |
View Market Depth
| Last trade - 15.48pm 30/08/2024 (20 minute delay) ? |
| OIL (ASX) Chart |